In the sequel to last week’s episode, we are back with Dr. Jonathan Davis, Director of the Heart Failure program from San Francisco General. We continue our tour of GDMT for HF, by covering SGLT2-i, MRAs, as well as some AKI and outpatient considerations. This is part 1 of 2 parts which will cover an overview of GDMT medications, and dive into Beta-blockers and ARNIs. Part 2 to come out next week!

| 00.33 - Previously on Booster Shots |

| 01.31 - Chapter 3: SGLT2-i |

• The now famous EMPA-REG OUTCOME trial [NEJM 2015]

• Empagliflozin in HFpEF (not discussed in this episode [NEJM 2021]

| 04.24 - Chapter 4: MRAs |

• RALES trial demonstrating benefit in Morbidity/Mortality [NEJM 1999]

| 10.04 - Organizing follow up |

| 11.51 - Issues with AKI |

| 15.10 - Some fun questions about Fun questions |

| 16.54 - Summary of All The Things! |

[The appearance of external hyperlinks does not constitute endorsements by UCSF of the linked websites, or the information, products, or services contained therein. UCSF does not exercise any editorial control over the information found therein, nor does UCSF make any representation of their accuracy or completeness. All information contained in this episode are the opinions of the respective speakers and not necessarily the views their respective institutions or UCSF, and is only provided for information purposes, not to diagnose or treat.]

Music by Amit Apte. Medical Heart Vectors by Vecteezy